Concepedia

Joost H. van den Berg

JH

27

Publications

1.7K

Citations

20

H-Index

1978

Active since

Affiliations

The Netherlands Cancer Institute(Current)

Oncode Institute

Slotervaartziekenhuis

Utrecht University

Molecular Oncology (United States)

Joost H. van den Berg is an author at The Netherlands Cancer Institute specializing in medicine, immunology, and vaccination.

ORCID

Top concepts

Publications per year

1978–2022

27

Publications

27

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

Maartje W. Rohaan, Troels Holz Borch, Joost H. van den Berg et al. · New England Journal of Medicine · 2022 · 474 citations · Full text

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy

Meike E. W. Logtenberg, J.H. Marco Jansen, Matthijs Raaben et al. · Nature Medicine · 2019 · 235 citations

, , +6

Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up

Joost H. van den Berg, Bianca Heemskerk, Nienke van Rooij et al. · Journal for ImmunoTherapy of Cancer · 2020 · 184 citations · Full text

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor

Joost H. van den Berg, Raquel Gomez-Eerland, B. van de Wiel et al. · Molecular Therapy · 2015 · 106 citations · Full text

Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity

Joost H. van den Berg, Koen Oosterhuis, Wim E. Hennink et al. · Journal of Controlled Release · 2009 · 73 citations

, , +11

Rows per page

1–5 of 27